High-grade B-cell lymphoma, not otherwise specified, presenting as primary peritoneal lymphomatosis and successfully treated with dose-adjusted EPOCH-R

被引:0
|
作者
Fujimi, Akihito [1 ,7 ]
Nagamachi, Yasuhiro [1 ]
Yamauchi, Naofumi [1 ]
Onoyama, Naoki [2 ]
Hayasaka, Naotaka [2 ]
Matsuno, Teppei [2 ]
Koike, Kazuhiko [2 ]
Goto, Yoshiro [2 ]
Ihara, Kohji [2 ]
Kato, Junji [2 ]
Nishisato, Takuji [2 ]
Kawase, Hiroshi [3 ]
Yano, Tomoyuki [3 ]
Kanaseki, Takayuki [4 ]
Sugita, Shintaro [5 ]
Kobune, Masayoshi [6 ]
机构
[1] Sapporo Kiyota Hosp, Dept Hematol, Sapporo, Japan
[2] Sapporo Kiyota Hosp, Dept Internal Med, Sapporo, Japan
[3] Sapporo Kiyota Hosp, Dept Hematol, Sapporo, Japan
[4] Sapporo Med Univ, Dept Pathol, Sapporo, Japan
[5] Sapporo Med Univ, Dept Surg Pathol, Sapporo, Japan
[6] Sapporo Med Univ, Dept Hematol, Sapporo, Japan
[7] Sapporo Kiyota Hosp, Dept Hematol, 1-1-1-1 Shin Ei,Kiyota Ward, Sapporo, Hokkaido 0040831, Japan
关键词
peritoneal lymphomatosis; high-grade B-cell lymphoma; MYC; DA-EPOCH-R; MIMICKING CARCINOMATOSIS; EXTENSIVE PERITONEAL; PET/CT FINDINGS; CT; INVOLVEMENT; CANCER;
D O I
10.3960/jslrt.23044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peritoneal lymphomatosis (PL) is a rare lymphoma-associated condition defined as the dissemination of lymphoma cells in the peritoneum. An 82-year-old man presented with abdominal pain, heartburn, and high fever. Radiological findings, including positron emission tomography-computed tomography (PET-CT), and gastrointestinal fiberscopy, showed diffuse thickening of the peritoneum, omentum, and mesentery; however, no lymphadenopathy, hepatosplenomegaly, or gastrointestinal lesions were observed. Under suspicion of peritonitis carcinomatosa of unknown origin, exploratory laparoscopy was performed that revealed multiple white nodules and masses on the surfaces of the peritoneum, mesentery, and intestinal serosa. The histopathological and cytogenetic findings of the peritoneum revealed high-grade B-cell lymphoma, not otherwise specified, and a gain of MYC by fluorescence in-situ hybridization. The patient was treated with two cycles of R-CHOP therapy, followed by six cycles of dose-adjusted EPOCH-R therapy, and a complete metabolic response was confirmed by PET-CT. Since there are no specific radiological findings to confirm the diagnosis of PL, a histopathological diagnosis is usually required. Most PL exhibit an aggressive lymphoma phenotype and can be cured by appropriate chemotherapy. Therefore, early diagnosis and treatment are desirable.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 50 条
  • [1] Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
    Giulino-Roth, Lisa
    O'Donohue, Tara
    Chen, Zhengming
    Bartlett, Nancy L.
    LaCasce, Ann
    Martin-Doyle, William
    Barth, Matthew J.
    Davies, Kimberly
    Blum, Kristie A.
    Christian, Beth
    Casulo, Carla
    Smith, Sonali M.
    Godfrey, James
    Termuhlen, Amanda
    Oberley, Matthew J.
    Alexander, Sarah
    Weitzman, Sheila
    Appel, Burton
    Mizukawa, Benjamin
    Svoboda, Jakub
    Afify, Zeinab
    Pauly, Melinda
    Dave, Hema
    Gardner, Rebecca
    Stephens, Deborah M.
    Zeitler, William A.
    Forlenza, Christopher
    Levine, Jennifer
    Williams, Michael E.
    Sima, Jody L.
    Bollard, Catherine M.
    Leonard, John P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (05) : 739 - 747
  • [2] Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma
    Malenda, Agata
    Kolkowska-Lesniak, Agnieszka
    Pula, Bartosz
    Dlugosz-Danecka, Monika
    Chelstowska, Monika
    Konska, Agnieszka
    Giza, Agnieszka
    Lech-Maranda, Ewa
    Jurczak, Wojciech
    Warzocha, Krzysztof
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (01) : 59 - 66
  • [3] Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
    Lakhotia, Rahul
    Melani, Christopher
    Roschewski, Mark
    Wilson, Wyndham H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (18) : 2063 - +
  • [4] The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R
    Wilson, WH
    Gutierrez, M
    O'Connor, P
    Frankel, S
    Jaffe, E
    Chabner, BA
    Grossbard, ML
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 41 - 47
  • [5] Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas
    Gharwan, Helen
    Lai, Catherine
    Grant, Cliona
    Dunleavy, Kieron
    Steinberg, Seth M.
    Shovlin, Margaret
    Fojo, Tito
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1616 - 1624
  • [6] Dose-Adjusted EPOCH-R is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma
    Ma'koseh, Mohammad
    Yaseen, Abeer
    Abu Abed, Nebras
    Shahin, Omar
    Abufara, Alaa
    Halahleh, Khalid
    Al-Rwashdeh, Mohammad
    Rahman, Zaid Abdel
    Alyaqoub, Maram
    Al-rabi, Kamal
    Abdel-Razeq, Hikmat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S488 - S488
  • [7] Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
    Lakhotia, Rahul
    Dunleavy, Kieron
    Abramson, Jeremy S.
    Link, Brian K.
    Powell, Bayard L.
    Melani, Christopher
    Lucas, Andrea N.
    Steinberg, Seth M.
    Friedberg, Jonathan W.
    Kahl, Brad S.
    Little, Richard F.
    Bartlett, Nancy L.
    Noy, Ariela
    Wilson, Wyndham H.
    Roschewski, Mark
    BLOOD ADVANCES, 2023, 7 (18) : 5320 - 5324
  • [8] High-grade B-cell lymphoma masquerading as peritoneal lymphomatosis
    Kareff, Samuel
    Yin, Chao
    Feigert, John
    BMJ CASE REPORTS, 2019, 12 (08)
  • [9] Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
    Lim, Kenneth J. C.
    Filshie, Robin
    LANCET HAEMATOLOGY, 2023, 10 (12): : E942 - E943
  • [10] Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement
    Kojima, Minoru
    Amaki, Jun
    Ogiya, Daisuke
    Ando, Kiyoshi
    Nakamura, Naoya
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2020, 60 (02) : 60 - 61